Catechol-O-Methyltransferase (COMT) Gene Variants Predict Response to Bupropion Therapy for Tobacco Dependence

Biological Psychiatry

Volumn 61, Issue 1, 2007, Pages 111-118

  Berrettini, Wade H ^a   Wileyto, E Paul ^a,b   Epstein, Leonard ^c   Restine, Stephanie ^a   Hawk, Larry ^c   Shields, Peter ^d   Niaura, Ray ^e   Lerman, Caryn ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

COMT; dopamine; nicotine dependence; Pharmacogenetics; smoking

Indexed keywords

AMFEBUTAMONE; CATECHOL METHYLTRANSFERASE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; BUPROPION; CATECHOL O-METHYLTRANSFERASE; CHI-SQUARE DISTRIBUTION; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; EXONS; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 33845197186     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.04.030     Document Type: Article

References (39)

1. Arinami T., Gao M., Hamaguchi H., and Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6 (1997) 577-582
2. Ascher J, Cole J, Colin J Bupropion (1995): A review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395-401.
3. Balfour D.J., Wright A.E., Benwell M.E., and Birrell C.E. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav Brain Res 113 (1995) 73-83
4. Benwell M.E., Balfour D.J., and Birrell C.E. Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine. Br J Pharmacol 114 (2000) 454-460
5. Berrettini W.H., and Lerman C.E. Pharmacotherapy and pharmacogenetics of nicotine dependence. Am J Psychiatry 162 (2005) 1441-1451
6. Bray N.J., Buckland P.R., Williams N.M., Williams H.J., Norton N., Owen M.J., and O'Donovan M.C. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 73 (2003) 152-161
7. Brown R., Burgess E., Sales S., and Whiteley J. Reliability and validity of a smoking timeline follow-back interview. Psychol Addict Behav 12 (1998) 101-112
8. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., et al. Functional analysis of genetic variation in catechol-o-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75 (2004) 807-821
9. Clayton D. Geneassoc: STATA modules for gene association analyses (2002), Cambridge Institute for Medical Research, Cambridge, UK
10. Colilla S., Lerman C., Shields P.G., Jepson C., Rukstalis M., Berlin J., et al. Association of Catechol-O-Methyltransferase with smoking cessation in two independent studies of women. Pharmacogenetics Genomics 15 (2005) 393-398
11. Dale L.C., Glover E.D., Sachs D.P., Schroeder D.R., Offord K.P., Croghan I.T., and Hurt R.D. Bupropion for smoking cessation: predictors of successful outcome. Chest 119 (2001) 1357-1364
12. de Leone J., Kiaz F.J., Rogers T., Browne D., and Dinsmore L. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr Res 56 (2002) 47-54
13. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 98 (2001) 6917-6922
14. Feyerabend C., and Russell M.A. A rapid gas-liquid chromatographic method for the determination of cotinine and nicotine in biological fluids. J Pharm Pharmacol 42 (1990) 450-452
15. Goldberg T.E., Egan M.F., Gscheidle T., Coppola R., Weickert T., Kolachana B.S., et al. Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 60 (2003) 889-896
16. Heatherton T.F., Kozlowski L.T., Frecker R.C., and Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86 (1991) 1119-1127
17. Hughes J.R., Keely J.P., Niaura R., Ossip-Klein D.J., Richmond R.L., and Swan G.E. Measure of abstinence in clinical trials: issues and recommendations. Nicotine Tobacco Res 5 (2003) 13-25
18. Hurt R., Sachs D., Glover E., Offord K., Johnston J., Dale L., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337 (1997) 1195-1202
19. Joober R., Gauthier J., Lal S., Bloom D., Lalonde P., Rouleau G., et al. COMT Val-108/158-Met gene variants associated with performance on the Wisconsin Card Sorting Test. Arch Gen Psychiatry 59 (2002) 662-663
20. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340 (1999) 685-691
21. Lerman C., Audrain J., Tercyak K., Hawk Jr. L.W., Bush A., Crystal-Mansour S., et al. Attention-deficit hyperactivity disorder (ADHD) symptoms and smoking patterns among participants in a smoking cessation program. Nicotine Tobacco Res 3 (2001) 353-359
22. Lerman C., Jepson C., Wileyto E.P., Epstein L.H., Rukstalis M., Patterson F., et al. The role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacol 31 (2006) 231-242
23. Lerman C., Patterson F., and Berrettini W. Treating tobacco dependence: state of the science and new directions. J Clin Oncology 23 (2005) 311-323
24. Lerman C., Shields P.G., Wileyto E.P., Audrain J., Hawk Jr. L.H., Pinto A., et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 22 (2003) 541-548
25. Malhotra A.K., Kestler L.J., Mazzanti C., Bates J.A., Goldberg T., and Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 159 (2002) 652-654
26. Mander A.P. Haplotype analysis in population-based association studies. Stata Journal 1 (2001) 58-75
27. Mander A.P. HAPIPF: Stata module to perform haplotype analysis (2002), Boston College, Chestnut Hill
28. Nisell M., Nomikos G.G., and Svensson T.H. Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol Toxicol 75 (1994) 348-352
29. Pontieri F., Tanda G., Orzi F., and Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382 (1996) 255-257
30. Pritchard J.K., Stephens M., and Donnelly P. Inference of population structure using multilocus genotype data. Genetics 155 (2000) 945-959
31. Redden D.T., Shields P.G., Epstein L., Wileyto E.P., Zakharkin S.O., Allison D.B., and Lerman C. The Catechol-O-Methyl-Transferase (COMT) functional polymorphism and nicotine dependence: An evaluation of non-replicated results. Cancer Epidemiol Biomarkers Prev 14 (2005) 1384-1389
32. Rice M.E., and Cragg S.J. Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci 7 (2004) 583-584
33. Sanchez C., and Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19 (1999) 467-489
34. Shield A.J., Thomae B.A., Eckloff B.W., Wieben E.D., and Weinshilboum R.M. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol Psychiatry 9 (2004) 151-160
35. Shifman S., Bronstein M., Sternfeld M., Pisanté-Shalom A., Lev-Lehman E., Weizman A., et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 71 (2002) 1296-1302
36. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Soc Res Nicotine Tobacco (2001) 149-159
37. Swan G.E., Valdes A.M., Ring H.Z., Khroyan T.V., Jack L.M., Ton C.C., et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenom J 5 (2005) 21-29
38. Thompson P.A., Shields P.G., Freudenheim J.L., Stone A., Vena J.E., Marshall J.R., et al. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 58 (1998) 2107-2110
39. Zhang H., and Sulzer D. Frequency-dependent modulation of dopamine release by nicotine. Nature Neurosci 7 (2004) 581-582